Asset Details
Do you wish to reserve the book?
Lactoferrin and lysozyme to reduce environmental enteric dysfunction and stunting in Malawian children: study protocol for a randomized controlled trial
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Lactoferrin and lysozyme to reduce environmental enteric dysfunction and stunting in Malawian children: study protocol for a randomized controlled trial
Do you wish to request the book?
Lactoferrin and lysozyme to reduce environmental enteric dysfunction and stunting in Malawian children: study protocol for a randomized controlled trial
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Lactoferrin and lysozyme to reduce environmental enteric dysfunction and stunting in Malawian children: study protocol for a randomized controlled trial
2017
Overview
Background
Chronic childhood malnutrition, as manifested by stunted linear growth, remains a persistent barrier to optimal child growth and societal development. Environmental enteric dysfunction (EED) is a significant underlying factor in the causal pathway to stunting, delayed cognitive development, and ultimately morbidity and mortality. Effective therapies against EED and stunting are lacking and further clinical trials are warranted to effectively identify and operationalize interventions.
Methods/design
A prospective randomized placebo-controlled parallel-group randomized controlled trial will be conducted to determine if a daily supplement of lactoferrin and lysozyme, two important proteins found in breast milk, can decrease the burden of EED and stunting in rural Malawian children aged 12–23 months old. The intervention and control groups will have a sample size of 86 subjects each. All field and laboratory researchers will be blinded to the assigned intervention group, as will the subjects and their caregivers. The percentage of ingested lactulose excreted in the urine (Δ%L) after 4 h will be used as the biomarker for EED and linear growth as the measure of chronic malnutrition (stunting). The primary outcomes of interest will be change in Δ%L from baseline to 8 weeks and to 16 weeks. Intention-to-treat analyses will be used.
Discussion
A rigorous clinical trial design will be used to assess the biologically plausible use of lactoferrin and lysozyme as dietary supplements for children at high risk for EED. If proven effective, these safe proteins may serve to markedly reduce the burden of childhood malnutrition and improve survival.
Trial Registration
Clinicaltrials.gov,
NCT02925026
. Registered on 4 October 2016.
Publisher
BioMed Central,Springer Nature B.V,BMC
Subject
/ Dietary Supplements - adverse effects
/ Environmental enteric dysfunction
/ Female
/ Growth Disorders - diagnosis
/ Growth Disorders - physiopathology
/ Growth Disorders - prevention & control
/ Humans
/ Infant
/ Infant Nutrition Disorders - diagnosis
/ Infant Nutrition Disorders - drug therapy
/ Infant Nutrition Disorders - physiopathology
/ Infant Nutritional Physiological Phenomena
/ Lactoferrin - adverse effects
/ Lactoferrin - therapeutic use
/ Lysozyme
/ Malawi
/ Male
/ Malnutrition - physiopathology
/ Medicine
/ Muramidase - adverse effects
/ Muramidase - therapeutic use
/ Sprue, Tropical - drug therapy
/ Sprue, Tropical - physiopathology
